



## FRAMEWORK

A vast array of metal compounds is used in medicine, ranging from nuclear imaging to direct treatment of cancer and parasitic diseases. Cisplatin, for example, is on the World Health Organization's List of Essential Medicines and used in more than 50% of chemotherapeutic treatments.

The objective of these 2 days is to raise awareness on the extended value of metal compounds in medicine through a wide-range of world-class case studies and numerous workshops centered on cutting edge issues.

The use of metal complexes in different areas of medicine will be discussed by eminent world-recognized specialists in the field.

### Join us!

**Early Bird Registration:** <https://goo.gl/forms/DEW8dfB4d3HAhis23>

**AUDIENCE :** *Engineers & Researchers*

**DURATION :**  
*1.5 days, 14-15 November 2019*

**LOCATION :**  
*Chimie ParisTech, 11, rue Pierre et Marie Curie, 75005 Paris*

**EARLY BIRDS FEES :**  
**400 €**, buffet included,  
*Preferential fees : 60% discount for academic partners, 75% discount for postdoctoral researchers, doctoral students, and students.*  
*\*valid offer until March 30<sup>th</sup> 2019*

## PROGRAM

### D1

#### RADIOIMAGING AND ANTIMALARIAL AGENTS IN PRECLINICAL TRIAL AND PHASES II AND III

##### 3 hour conference

- Ferroquine, phase II, antimalarial drug candidate from Sanofi.
- A <sup>89</sup>Zr complex in pre-clinical phase against cancer.
- A <sup>99m</sup>Tc complex in phase III clinical trial against prostate cancer.

### D2

#### METAL COMPLEXES AGAINST CANCER IN PRECLINICAL TRIAL AND PHASE II CLINICAL TRIAL

##### 4 hour conference

- A Ruthenium complex in preclinical phase against cancer.
- A Ruthenium complex beginning clinical phase II trials and Gallium complex against bone malignancies and bone disorders also beginning phase II clinical trials.
- A Ruthenium complex as a Photodynamic Therapy (PDT) agent in phase I clinical trial against cancer.
- A ferrocenyl compounds in preclinical phase against cancer.

##### 2 hour workshop

- Why and how metal complexes are used against cancer

## SPEAKERS




**GILLES GASSER**  
**WORKSHOP ORGANIZER**  
 gilles.gasser@chimieparistech.psl.eu  
 Chimie ParisTech, PSL University (France)  
 Discoverer of a chelator for  $^{89}\text{Zr}$  currently in pre-clinical trial for cancer imaging.



**CHRISTOPHE BIOT**  
 University of Lille (France)  
 Discoverer of Ferroquine, a ferrocene-containing agent currently in phase IIb against malaria.



**BERNARD KEPPLER**  
 University of Vienna (Austria)  
 Discoverer of IT-139 (former KP1339) and LX-001 (former KP46), a ruthenium complex and a gallium complex beginning phase II clinical trials against cancer.



**ROGER ALBERTO**  
 University of Zurich (Switzerland)  
 Discoverer of a chelator for  $^{99\text{m}}\text{Tc}$  currently in phase III clinical trial for prostate cancer imaging.



**SHERRI MCFARLAND**  
 University of North Carolina at Greensboro (USA)  
 Discoverer of TLD 1433, a ruthenium-containing PDT agent that successfully completed a Phase Ib clinical trial against bladder cancer, with Phase II pending.



**PAUL DYSON**  
 EPFL (Switzerland)  
 Discoverer of a ruthenium-containing agent currently in pre-clinical trial against cancer.



**GERARD JAOUEN**  
 Chimie ParisTech, PSL University (France)  
 Discoverer of Ferrocifen, an iron-containing agent currently in pre-clinical trial against cancer.

## OTHER SERVICES ON THE SUBJECT

Customized training:  yes  no

On-site training:  yes  no

Consulting:  yes  no

## CONTACT

formation.continue@chimie-paristech.fr  
 +33 (0) 1 44 27 80 97